Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.47 |
| ▸ | NAAA | Q02083 | 1/20 | 0.44 |
| ▸ | MMP3 | P08254 | 1/20 | 0.43 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
| ▸ | TNF | P01375 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
| ▸ | MIF | P14174 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | AGXT | P21549 | 1/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | RXRB | P28702 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL37742 | 0.93 | IDO1 (0.46) | MAOBIDO1LOXL2MAOATAAR1 | |
| Potassium Ion SCHEMBL27559718 | 0.88 | IDO1 (0.42) | MAOBIDO1LOXL2MAOATAAR1 | |
| SCHEMBL23137321 | 0.88 | MMP3 (0.50) | MMP3TNFCYP11B1CYP11B2FLT3 | |
| SCHEMBL196175 | 0.88 | MMP3 (0.50) | MMP3TNFCYP11B1CYP11B2FLT3 | |
| SCHEMBL9953772 | 0.86 | IDO1 (0.41) | MAOBIDO1LOXL2MAOATAAR1 | |
| SCHEMBL30439382 | 0.81 | MMP3 (0.50) | MMP3TNFCYP11B1CYP11B2FLT3 | |
| SCHEMBL18069859 | 0.81 | MMP3 (0.70) | MMP3CYP11B1CYP11B2TAAR1AGXT | |
| SCHEMBL29644934 | 0.80 | TNF (0.39) | MMP3TNFCYP11B1CYP11B2FLT3 | |
| SCHEMBL2154504 | 0.80 | KMT2A (0.47) | MMP3LOXL2TNFFLT3KMT2A | |
| SCHEMBL343612 | 0.79 | MMP3 (0.53) | NAAAMMP3PYCR1IDO1TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3283459-B1 | MOLECULES HAVING PESTICIDAL UTILITY, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES, RELATED THERETO | DOW AGROSCIENCES LLC (US) | 2019-05-22 | — | — | EP | disclosed |
| EP-1590321-B1 | ARYL ALKYL CARBAMATE DERIVATIVES PRODUCTION AND USE THEREOF IN THERAPY | SANOFI AVENTIS (FR) | 2010-04-28 | — | — | EP | disclosed |
| US-7632850-B2 | 2-amino-2-oxoethyl 1-(4'-fluoro-1,1'-biphenyl-4-yl)cyclopropylmethylcarbamate and 2-(methylamino)-2-oxoethyl 1-(4'-fluoro-1,1'-biphenyl-4-yl)cyclopropylmethylcarbamate; fatty acid amide (FAAH) hyrdrolase inhibitors; analgesics; neuropathic pain;psychological disorders; anticarcinogenic agents; AIDS | SANOFI-AVENTIS (FR) | 2009-12-15 | — | — | US | disclosed |
| US-20060014830-A1 | Arylalkylcarbamate derivatives production and use thereof in therapy | SANOFI-AVENTIS (FR) | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014830-A1 | Arylalkylcarbamate derivatives production and use thereof in therapy | CBR3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C5 | MAOB 379/4885NAAA 1697/4885MMP3 2924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.